Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...

Detailed price information for Goldman Sachs Group (GS-N) from The Globe and Mail including charting and trades.

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

They are large molecule drugs, so complex in structure and must be administered by injection. Importantly, Novo Nordisk's and Lilly's weight loss drugs have been highly efficacious, and demand has ...